<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03114904</url>
  </required_header>
  <id_info>
    <org_study_id>PI2015_843_0019</org_study_id>
    <nct_id>NCT03114904</nct_id>
  </id_info>
  <brief_title>Comparison of the Efficacy of a Protocol for the Withdrawal of Neurosedation From the Usual Strategy in Cerebroses</brief_title>
  <acronym>NEUROSEV</acronym>
  <official_title>Comparison of the Efficacy of a Protocol for the Withdrawal of Neurosedation From the Usual Strategy in Cerebroses: Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The withdrawal syndrome in benzodiazepines and morphine is common in intensive care, the
      incidence is estimated at 32.1%.

      Cerebrospatized patients are probably more prone to withdrawal because they require high
      doses of sedation.

      Moreover, this syndrome is probably deleterious on the cerebral hemodynamics (high point of
      the therapeutic management).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2016</start_date>
  <completion_date type="Anticipated">May 16, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 16, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A variation of the Jasinski score between H0 (stop sedation) and H6. This score measures the signs of withdrawal</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Withdrawal Syndrome</condition>
  <condition>Cerebral Lesion</condition>
  <arm_group>
    <arm_group_label>&quot;Usual&quot; weaning management</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Introduction to H2 for the discontinuation of therapeutics</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Variation of Jasinski score between H0 (stop of sedatives) and H6</intervention_name>
    <description>To compare the effectiveness of a withdrawal management protocol with the usual management in cerebral patients (Subarachnoid haemorrhage (HSA), stroke and head trauma (CT))</description>
    <arm_group_label>&quot;Usual&quot; weaning management</arm_group_label>
    <arm_group_label>Introduction to H2 for the discontinuation of therapeutics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Major Patient

          -  Admitted in Neuroreanimation

          -  Cerebroséé (TC-HSA-AVC)

          -  Mono or multi failing

          -  After a neurosedation ≥ 3 days by hypnotic type benzodiazepine (Midazolam®) and
             morphinomimetic (Sufentanyl®) in IVSE

          -  Affiliation to Social Security

          -  Agreement of the person of confidence

        Exclusion Criteria:

          -  Addiction to opiates, cocaine or cannabis

          -  Neurological Pathology Before Hospitalization

          -  Patient suffering from cardiac arrest

          -  Pregnant woman

          -  Sedation window

          -  Patient under tutelage or curatorship or deprived of public law
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexis SALOMON, Dr</last_name>
    <phone>+33322087868</phone>
    <email>salomon.alexis@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens Picardie</name>
      <address>
        <city>Amiens</city>
        <state>Picardie</state>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexis SALOMON, Dr</last_name>
      <phone>+33322087868</phone>
      <email>salomon.alexis@chu-amiens.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2017</study_first_submitted>
  <study_first_submitted_qc>April 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>May 11, 2017</last_update_submitted>
  <last_update_submitted_qc>May 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance Withdrawal Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypnotics and Sedatives</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

